Meeting
2019 Genitourinary Cancers Symposium
Predicting vital retroperitoneal residual tumors of metastatic testicular tumor patients after chemotherapy using radiomics.
Authors
Tim Nestler
Department of Urology and Uro-Oncology, University Hospital of Cologne, Cologne, Germany
Tim Nestler , Bettina Baeßler , Daniel Pinto dos Santos , David J. K. P. Pfister , David Maintz , Axel Heidenreich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Testicular Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 527)
DOI
10.1200/JCO.2019.37.7_suppl.527
Abstract #
527
Poster Bd #
M14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.
First Author: Bendu Konneh
Poster
2018 Genitourinary Cancers Symposium
Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes.
First Author: Lucia Nappi
Poster
2017 Genitourinary Cancers Symposium
Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase II Pazotest trial.
First Author: Andrea Necchi
Poster
2014 Genitourinary Cancers Symposium
Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.
First Author: Patrizia Giannatempo